Terence Ketter

Publication Details

  • Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients ARCHIVES OF GENERAL PSYCHIATRY Marangell, L. B., George, M. S., Callahan, A. M., Ketter, T. A., Pazzaglia, P. J., LHerrou, T. A., Leverich, G. S., Post, R. M. 1997; 54 (3): 214-222


    Therapeutic effects of the tripeptide protirelin (thyrotropin-releasing hormone) have been postulated in the affective disorders, but direct assessment in humans has been hindered by poor blood-brain barrier permeability.Eight medication-free inpatients with refractory depression received 500 micrograms of protirelin via a lumbar intrathecal injection and an identical sham lumbar puncture procedure, separated by 1 week, in a double-blind crossover design.Five of eight patients responded to intrathecal protirelin, defined as a 50% or greater reduction in an abbreviated Hamilton Rating Scale for Depression score. Suicidality also was reduced significantly (P < .05). Responses were rapid and clinically robust, but short-lived.Administration of protirelin by an intrathecal route induced a rapid improvement in mood and suicidality in these refractory depressed patients, supporting the hypothesis that thyrotropin-releasing hormone could be a positive modulator of mood.

    View details for Web of Science ID A1997WP35500004

    View details for PubMedID 9075462

Stanford Medicine Resources:

Footer Links: